The latest news, trends, analysis, interviews and podcasts from the global food and beverage industry

Biotech company Allozymes has secured $15 million in a Series A funding round led by France's Seventure Partners and Singapore-based Xora Innovation. The funding round included new investors such as NUS Technology Holdings and Thia Ventures, while SOSV and Entrepreneur First continued their investment in the company. Allozymes' core technology is its proprietary microfluidic platform, which, according to the company, has the industry's fastest enzyme screening capability, analysing over 20 million variants daily. This results in a 200x higher chance of success in developing custom enzymes with precise properties for specific industrial applications. As well as its ultra-high-throughput screening, Allozymes boasts strong enzyme sorting and detection capabilities. This enables the company to identify promising enzyme candidates and accurately pair them with specific industrial requirements, tackling a critical bottleneck in conventional enzyme discovery approaches. The investment supports Allozymes' expansion into Europe and fosters strategic partnerships in the food and chemical industries, 'while paving the way for new partnerships in the pharmaceutical and life science industries,' said the company. The funding will also support the development of a comprehensive enzyme data library for future discoveries. The funding will enhance Allozymes' development of the industry's most extensive enzyme data library. This data will fuel powerful AI/ML algorithms to predict and produce innovative, reliable biocatalytic solutions for diverse industries. Peyman Salehian, CEO and co-founder of Allozymes, said: "We are thrilled to have secured this funding from a distinguished group of investors who share our vision for the transformative potential of enzymes. This investment is a testament to our progress in developing a truly unique and powerful enzyme engineering platform. We are committed to unlocking the full potential of enzymes for a more sustainable and efficient future." Allozymes' CTO Akbar Vahidi added: "Our platform represents a significant step forward in democratizing access to powerful enzymatic solutions. By providing a centralised platform for enzyme discovery and engineering, we aim to empower researchers and companies of all sizes to harness the potential of enzymes and accelerate innovation across various industries."